Introduction

This page provides a comprehensive analysis of the known insider trading history of Fitzpatrick Mark J.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Fitzpatrick Mark J. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ALNA / Allena Pharmaceuticals Inc Director 5,000
President 363,352
US:AEGR / Aegerion Pharmaceuticals, Inc. Chief Financial Officer 10,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Fitzpatrick Mark J.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Fitzpatrick Mark J. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2021-04-08 3 ALNA Allena Pharmaceuticals, Inc.
Common Stock
5,000
2021-04-08 2021-04-06 4 ALNA Allena Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 74,000 74,000
2020-12-07 2020-12-04 4 CHMA CHIASMA, INC
Stock Option (Right to Buy)
M - Exercise -10,000 363,352 -2.68
2020-12-07 2020-12-04 4 CHMA CHIASMA, INC
Common Stock
M - Exercise 10,000 19,612 104.04 2.60 26,000 50,991
2020-02-18 2020-02-14 4 CHMA CHIASMA, INC
Stock Option (Right to Buy)
A - Award 150,000 150,000
2019-02-15 2019-02-14 4 CHMA CHIASMA, INC
Stock Option (Right to Buy)
A - Award 186,000 186,000
2018-12-21 2018-12-20 4 CHMA CHIASMA, INC
Common Stock
P - Purchase X 9,612 9,612 2.50 24,030 24,030
2018-02-26 2018-02-23 4 CHMA CHIASMA, INC
Stock Option (Right to Buy)
A - Award 67,967 67,967
2018-02-26 2018-02-23 4 CHMA CHIASMA, INC
Stock Option (Right to Buy)
A - Award 194,183 194,183
2016-10-25 2016-10-25 4 CHMA CHIASMA, INC
Stock Option (right to buy)
A - Award 373,352 373,352
2016-02-12 2016-02-10 4 CHMA CHIASMA, INC
Stock Option (right to buy)
A - Award 70,000 70,000
2015-04-03 2015-04-01 4 AEGR Aegerion Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2015-04-03 2015-04-01 4 AEGR Aegerion Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 40,000 40,000
2015-01-05 2014-12-31 4 AEGR Aegerion Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 65,000 65,000
2014-08-20 2014-08-19 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
P - Purchase 1,150 9,500 13.77 30.64 35,236 291,080
2014-04-21 2014-04-01 4 AEGR Aegerion Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 20,000 20,000
2014-03-05 2014-03-04 4 AEGR Aegerion Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -2,500 189,650 -1.30
2014-03-05 2014-03-04 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
M - Exercise 2,500 8,350 42.74 17.64 44,100 147,294
2014-02-12 2014-02-10 4 AEGR Aegerion Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -7,500 192,150 -3.76
2014-02-12 2014-02-10 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -486 5,850 -7.67 64.69 -31,439 378,436
2014-02-12 2014-02-10 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -900 6,336 -12.44 63.72 -57,348 403,730
2014-02-12 2014-02-10 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -2,814 7,236 -28.00 62.94 -177,113 455,434
2014-02-12 2014-02-10 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -3,300 10,050 -24.72 61.71 -203,643 620,186
2014-02-12 2014-02-10 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
M - Exercise 7,500 13,350 128.21 17.64 132,300 235,494
2014-02-12 2013-11-18 5 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
G - Gift 100 100
2014-02-12 2013-11-18 5 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
G - Gift -100 5,750 -1.71
2013-11-13 2013-11-13 4 AEGR Aegerion Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -2,850 199,650 -1.41
2013-11-13 2013-11-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -7,500 202,500 -3.57
2013-11-13 2013-11-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
M - Exercise 2,850 5,850 95.00 17.64 50,274 103,194
2013-11-13 2013-11-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -1,800 3,000 -37.50 80.03 -144,057 240,095
2013-11-13 2013-11-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -4,478 4,800 -48.26 79.34 -355,300 380,848
2013-11-13 2013-11-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -622 9,278 -6.28 78.38 -48,755 727,255
2013-11-13 2013-11-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -200 9,900 -1.98 76.14 -15,228 753,786
2013-11-13 2013-11-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -200 10,100 -1.94 74.43 -14,886 751,743
2013-11-13 2013-11-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -200 10,300 -1.90 73.01 -14,602 752,029
2013-11-13 2013-11-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
M - Exercise 7,500 10,500 250.00 17.64 132,300 185,220
2013-08-28 2013-08-26 4 AEGR Aegerion Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -2,500 210,000 -1.18
2013-08-28 2013-08-26 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
M - Exercise 2,500 3,000 500.00 17.64 44,100 52,920
2013-08-16 2013-08-14 4 AEGR Aegerion Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -7,500 212,500 -3.41
2013-08-16 2013-08-14 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -588 500 -54.04 94.44 -55,531 47,220
2013-08-16 2013-08-14 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -4,400 1,088 -80.17 93.71 -412,324 101,956
2013-08-16 2013-08-14 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
S - Sale X -2,512 5,488 -31.40 92.74 -232,960 508,952
2013-08-16 2013-08-14 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
M - Exercise 7,500 8,000 1,500.00 17.64 132,300 141,120
2013-04-03 2013-04-01 4 AEGR Aegerion Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 27,500 27,500
2012-03-26 2012-03-23 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
P - Purchase 300 500 150.00 14.15 4,244 7,074
2012-03-26 2012-03-23 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock
P - Purchase 200 200 14.16 2,832 2,832
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)